PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Greg Rossi Selected Research
Anemia
10/2007
Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.
10/2007
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
10/2007
Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks.
06/2007
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
06/2007
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
05/2006
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
02/2006
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
12/2005
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
01/2004
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
11/2003
A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Articles by Research Topic
Disease
10
Anemia
10/2007 - 11/2003
2
Neoplasms (Cancer)
06/2007 - 01/2004
1
Breast Neoplasms (Breast Cancer)
12/2005
1
Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/2005
Drug/Important Bio-Agent (IBA)
10
darbepoetin alfa (Aranesp)
FDA Link
10/2007 - 11/2003
5
Epoetin Alfa (Epogen)
FDA Link
05/2006 - 11/2003
Therapy/Procedure
9
Drug Therapy (Chemotherapy)
10/2007 - 11/2003